Abstract Title:

Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)

Summary:

The DREAMM-8 study compared the effectiveness and safety of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) to pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM). ​ The study showed that BPd significantly improved progression-free survival (PFS) compared to PVd, with a higher 12-month PFS rate. ​ BPd also resulted in a higher overall response rate and a greater rate of complete response or better. ​ The duration of response was longer with BPd. ​ Adverse events were reported in both groups, but ocular adverse events were more common with BPd. ​ The safety profile of both treatments was manageable. ​ These findings suggest that BPd is a promising treatment option for RRMM patients. ​

Key Points:

• The DREAMM-8 study demonstrated a significant and clinically meaningful improvement in progression-free survival (PFS) with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) compared to pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM). ​
• The 12-month PFS rate was higher in the BPd arm (71% vs 51%). ​
• The overall response rate (ORR) was 77% in the BPd arm and 72% in the PVd arm, with a higher rate of complete response or better in the BPd arm (40% vs 16%). ​
• The median duration of response was not reached in the BPd arm and was 17.5 months in the PVd arm. ​
• Adverse events (AEs) were reported in over 99% of patients in the BPd arm and 96% in the PVd arm, with ocular AEs being more common in the BPd arm (grade 3/4 in 43% vs 2% in the PVd arm). ​
• The safety profile of both regimens was manageable and consistent with the known safety profile of the individual agents. ​

Authors:

Suzanne Trudel, Meral Beksac, Luděk Pour, Sosana Delimpasi, Hang Quach, Vladimir I. Vorobyev, Michele Cavo, Kazuhito Suzuki, Pawel Robak, Kristin Morris, Amy Phillips-Jones, Xiaoou Linnette Zhou, Giulia Fulci, Neal Sule, Brandon Kremer, Joanna Opalinska, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos

Clinical Trial Registration Number: NCT04484623 (https://classic.clinicaltrials.gov/ct2/show/NCT04484623)
ASCO Abstract# LBA105 (https://meetings.asco.org/abstracts-presentations/234910)
DOI: 10.1200/JCO.2024.42.17_suppl.LBA105 (https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA105)